{'fraction_non_alphanumeric': 0.023029229406554472, 'fraction_numerical': 0.015057573073516387, 'mean_word_length': 5.807228915662651, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Abstract 150: Phosphodiesterase 5 Inhibition Mitigates I-r Injury in a Model of Vascularized Composite Allotransplantation

RESULTS: Obese animals treated with the iNOS inhibitor showed profound increases in Tc99 lymph node uptake, lymphatic pumping capacity (as assessed by ICG lymphangiography), and dendritic cell trafficking to peripheral lymph nodes (2-4 fold increase as compared with controls). Furthermore, transplanted DCs injected into the footpads of experimental animals 16 hours prior to harvesting were found to compromise 2.24 times more of the inguinal and popliteal lymph node cell populations in the iNOS inhibited obese animals. Histologic analysis showed that iNOS inhibited obese animals had markedly decreased iNOS expression and a profound decrease in perilymphatic iNOS+ cells. Interestingly, iNOS inhibition did not decrease general or perilymphatic inflammation, as tissue CD45+ cell counts and perilymphatic CD45+ cell counts were not significantly decreased in iNOS inhibited animals. In addition, short term iNOS inhibition did not change serum HDL, LDL, triglyceride, cholesterol and glucose levels.